Document is current

Any future updates will be listed below

Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial

Crossref DOI link: https://doi.org/10.1038/s41467-026-68736-2

Published Online: 2026-01-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark